Sarepta Therapeutics Inc (SRPT) was Reiterated by Needham to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 81 from a previous price target of $47 . Needham advised their investors in a research report released on Sep 20, 2016.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Company shares were Reiterated by Robert W. Baird on Sep 19, 2016 to “Outperform”, Firm has raised the Price Target to $ 102 from a previous price target of $23 .Company shares were Upgraded by RBC Capital Mkts on Sep 19, 2016 to ” Outperform”, Firm has raised the Price Target to $ 83 from a previous price target of $5 .Sarepta Therapeutics Inc was Upgraded by Jefferies to ” Hold” on Sep 19, 2016.
On the company’s financial health, Sarepta Therapeutics Inc reported $-1.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $-1.21.Analysts expectations of $ .10.During the same quarter in the previous year, the company posted $-0.87 EPS.
Sarepta Therapeutics Inc closed down -1.87 points or -6.23% at $28.15 with 4,374,537 shares getting traded on Friday. Post opening the session at $29.4, the shares hit an intraday low of $27.9901 and an intraday high of $29.93 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Sep 16, 2016, Edward M. Md Kaye (SVP Interim CEO & CMO) sold 24,557 shares at $30.00 per share price. According to the SEC, on Mar 16, 2016, M Kathleen Behrens (director) purchased 75,000 shares at $15.54 per share price. On Mar 16, 2016, Ben Gil Price (director) purchased 4,500 shares at $16.70 per share price, according to the Form-4 filing with the securities and exchange commission.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.